wsj.com
GSK to Buy 35Pharma for $950 Million
GSK struck a deal to buy Canada's 35Pharma as the U.K. drugmaker seeks to bolster its exposure to diseases linked to obesity.
GSK plcGSKNYSE
Loading
Latest News
Loading news...
proactiveinvestors.co.uk
GSK pays $950m for a pulmonary hypertension drug designed to avoid the bleeding risk that limits rival treatments
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, securing a clinical-stage drug for pulmonary hypertension that its new owner believes can improve on the safety profile of existing therapies in a market forecast to reach $18 billion by 2032. The asset at the centre of the deal is HS235, an activin signalling inhibitor that has completed phase I healthy volunteer trials and is preparing to enter studies in two forms of the disease: pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction.
proactiveinvestors.com
GSK pays $950m for a pulmonary hypertension drug designed to avoid the bleeding risk that limits rival treatments
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, securing a clinical-stage drug for pulmonary...
reuters.com
GSK to buy 35Pharma for $950 million
GSK on Wednesday agreed to buy Canadian biopharmaceutical company 35Pharma Inc for $950 million in cash.
globenewswire.com
35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)
MONTREAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics today announced it has entered into an agreement with GSK plc (GSK), under which GSK will acquire all of the outstanding equity interests in 35Pharma. The acquisition includes HS235, a potential best-in-class investigational medicine that has completed phase I healthy volunteer clinical trials with studies to start imminently in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
gurufocus.com
GSK Strikes $1 Billion China RNA Deal
GSK plc (GSK) is making a calculated bet on next generation gene silencing drugs, signing a licensing agreement worth up to $1 billion with China's Frontier Bio
reuters.com
Frontier Biotechnologies strikes up to $1 billion deal with GSK
Frontier Biotechnologies said on Tuesday it has struck a deal with GSK , granting the British drugmaker worldwide rights to develop two small interfering RNA therapies targeting kidney diseases in an agreement that could be worth up to $1 billion.
businesswire.com
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract.
defenseworld.net
GSK Sees Unusually High Options Volume (NYSE:GSK)
GSK PLC Sponsored ADR (NYSE: GSK - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Stock traders purchased 81,873 call options on the stock. This represents an increase of 1,106% compared to the average daily volume of 6,790 call options. Analyst Ratings Changes GSK has been the topic of several
defenseworld.net
GSK (NYSE:GSK) Share Price Passes Above Two Hundred Day Moving Average – What’s Next?
GSK PLC Sponsored ADR (NYSE: GSK - Get Free Report) passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $46.15 and traded as high as $61.70. GSK shares last traded at $61.2080, with a volume of 5,389,786 shares trading hands. Wall Street
businesswire.com
GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
PHILADELPHIA--(BUSINESS WIRE)--GSK's AREXVY associated with reductions in certain RSV-related risks, real world study shows.
seekingalpha.com
GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade)
GSK plc is a pharma worthy of a Buy rating, based on past performance and future prospects. In 2025, the company grew revenues by 7% and core EPS by 12%. GSK seems to have successfully pivoted into a "pure-play" Pharma having ditched its consumer healthcare division - despite some looming patent expiries, its pipeline looks promising enough to cope.
gurufocus.com
Mark Hillman's Strategic Move: Significant Addition to State Street SPDR S&P 500 ETF Trust
Insight into Mark Hillman (Trades, Portfolio)'s Fourth Quarter 2025 Investment Moves Mark Hillman (Trades, Portfolio) recently submitted the 13F filing for the
gurufocus.com
Kahn Brothers Reduces Stake in Pfizer Inc by 21.66%
Insights from Kahn Brothers (Trades, Portfolio)' Fourth Quarter 2025 13F Filing Kahn Brothers (Trades, Portfolio) recently submitted their 13F filing for the f
proactiveinvestors.co.uk
Citi lifts GSK target price but keeps neutral stance after rally
Citi has raised its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 while maintaining a 'neutral' rating, citing a sharp rally driven by improving investor sentiment. The broker said full-year 2025 earnings per share were 2% ahead of consensus, with constant exchange rate guidance for 2026 broadly in line with expectations.
proactiveinvestors.com
Citi lifts GSK target price but keeps neutral stance after rally
Citi has raised its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 while maintaining a 'neutral' rating, citing a sharp rally driven by improving...
zacks.com
GSK Gets EU Approval for Expanded Use of Nucala in COPD
GSK secures EU approval for Nucala, an add-on maintenance treatment for chronic obstructive pulmonary disease in adults.
proactiveinvestors.co.uk
ShoreCap says GSK has cracked it and the £40bn prize is now in sight
Yesterday's results looked solid. Today Shore Capital goes further, arguing GSK has effectively delivered its medium-term plan a year early and that a £40 billion revenue ambition for 2031 is now credible, with 2,500p “justifiable” on the shares.
proactiveinvestors.com
ShoreCap says GSK has cracked it and the £40bn prize is now in sight
Yesterday’s results looked solid. Today Shore Capital goes further, arguing GSK has effectively delivered its medium-term plan a year early and that a £40...
defenseworld.net
GSK Q4 Earnings Call Highlights
GSK (NYSE: GSK) executives struck an upbeat tone on the company's full-year 2025 results call, pointing to broad-based sales growth, operating leverage, and a pipeline they said is gaining momentum. Management also outlined priorities for 2026 centered on maximizing key launches, accelerating late-stage assets, and continuing business development (BD) while simplifying operations and increasing use of